Expertise in
6
conditions

Adlette Inati

Tripoli, AS, LB 
Expertise in
6
conditions
Tripoli, AS, LB 

Overview

Adlette Inati practices practicing medicine in Tripoli, Lebanon.

Inati is highly rated in 6 conditions, according to our data. Their clinical expertise encompasses Congenital Hemolytic Anemia, Hemolytic Anemia, Hemoglobinopathy, Anemia, and Splenectomy.

They are actively involved in clinical research, co-authoring 47 peer reviewed articles and participating in 5 clinical trials.

Locations

Tripoli, AS, Lebanon
Other Locations
Jbail, JL, Lebanon
Balamand, Lebanon
Beirut, BA, Lebanon

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises
Enrollment Status: Completed
Publish Date: December 02, 2025
Intervention Type: Drug
Study Drug: Inclacumab
Study Phase: Phase 3
A Phase 2a, Open-label, Single and Multiple Dose Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Treatment Effect of GBT440 in Pediatric Participants With Sickle Cell Disease
A Phase 2a, Open-label, Single and Multiple Dose Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Treatment Effect of GBT440 in Pediatric Participants With Sickle Cell Disease
Enrollment Status: Terminated
Publish Date: August 15, 2025
Intervention Type: Drug
Study Drug: Voxelotor
Study Phase: Phase 2
A Randomized, Double-blind, Placebo-controlled, Multicenter Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises
A Randomized, Double-blind, Placebo-controlled, Multicenter Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises
Enrollment Status: Terminated
Publish Date: December 11, 2024
Intervention Type: Drug
Study Drug: Inclacumab
Study Phase: Phase 3
ESTIMATION OF THE DISEASE BURDEN AND PREVALENT GENOTYPES OF ROTAVIRUS (RV) CAUSING GASTROENTERITIS (GE) IN CHILDREN <5 YEARS OF AGE IN LEBANON BASED ON A SENTINEL HOSPITAL-BASED SURVEILLANCE PROGRAM.
ESTIMATION OF THE DISEASE BURDEN AND PREVALENT GENOTYPES OF ROTAVIRUS (RV) CAUSING GASTROENTERITIS (GE) IN CHILDREN <5 YEARS OF AGE IN LEBANON BASED ON A SENTINEL HOSPITAL-BASED SURVEILLANCE PROGRAM.
Enrollment Status: Completed
Publish Date: November 18, 2023
A Multi-Centre, Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Investigate Efficacy and Safety of Sevuparin Infusion for the Management of Acute Vaso-Occlusive Crisis (VOC) in Subjects With Sickle-Cell Disease (SCD).
A Multi-Centre, Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Investigate Efficacy and Safety of Sevuparin Infusion for the Management of Acute Vaso-Occlusive Crisis (VOC) in Subjects With Sickle-Cell Disease (SCD).
Enrollment Status: Completed
Publish Date: July 16, 2019
Intervention Type: Drug, Other
Study Phase: Phase 2
View 4 Less Clinical Trials

47 Total Publications

MENA Delphi consensus on iron deficiency anemia in infants and young children: screening, management, and prevention strategies.
MENA Delphi consensus on iron deficiency anemia in infants and young children: screening, management, and prevention strategies.
Journal: Frontiers in nutrition
Published: March 20, 2026

Frequently Asked Questions about Adlette Inati

Is Adlette Inati a top-rated expert for Congenital Hemolytic Anemia?

MediFind is an objective health platform that identifies experts based on real-world data. Adlette Inati is classified as an Advanced expert for Congenital Hemolytic Anemia, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Adlette Inati participate in research or clinical trials?

Yes. Adlette Inati has published 47 articles and abstracts on conditions like Congenital Hemolytic Anemia. You can view a list of Adlette Inati's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Inati's expertise for a condition
ConditionClose
      View All 11 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile